|
Company:
|
DENALI THERAPEUTICS INC. (DNLI)
|
|
Form Type:
|
8-K
|
|
Filing Date:
|
8/6/2019
|
|
CIK:
|
0001714899
|
|
Address:
|
161 OYSTER POINT BLVD.
|
|
City, State, Zip:
|
SOUTH SAN FRANCISCO, California 94080
|
|
Telephone:
|
(650) 866-8548
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$15.38
|
Change:
0.18 (1.18%)
|
Trade Time:
Oct 11
|
Market Cap:
$1.47B
|
|
|
|
|
|
|
Description of Business
|
|
Neurodegeneration represents one of the most significant unmet medical needs of
our time, with few effective therapeutic options available for patients with
Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis ("ALS"),
and other neurodegenerative diseases. The burden of these diseases to patients
and society is massive.
We believe the time is right to make a strong and ambitious effort to defeat
neurodegeneration. We believe that we can succeed in a field that has seen
limited success in the past, because of our team of experienced and passionately
dedicated scientists and drug developers, our focused scientific strategy, and
our proprietary blood-brain barrier ("BBB"), platform delivery technology. We
are developing a broad portfolio of targeted therapeutic candidates for
neurodegenerative diseases and currently have two programs in Phase 1 clinical
development.
|
|
|
|